

Tuesday, 28 March 2023

Justin Nelson

Principal Adviser, Listings Compliance

To Justin,

Response to price query

We refer to a price query by the Australian Securities Exchange dated 28 March 2023.

In response to the specific questions of the price query and using the same numbering:

1. The Company is not aware of any information concerning it that has not been announced which, if known, may explain the recent trading pattern in the securities of NeuRizer Ltd. The Company does not give earnings guidance as the Company does not have revenue.
2. Not applicable.
3. On 10 March 2023 the Company announced the appointment of Barrenjoey Capital Partners as financial and corporate advisor. On 15 March 2023 the Company provided an update to this announcement with further information. The Company has stated on many occasions that it is in the process of securing a strategic partner for the NeuRizer Urea Project but at this stage no definitive binding agreements with a strategic partner have been entered into.
4. NeuRizer Ltd confirms that it is in compliance with the ASX listing rules and, in particular, with listing rule 3.1.
5. The Company confirms that this letter has been approved by its board.

Yours sincerely,



Jordan Mehrtens

Company Secretary



28 March 2023

Reference: 71460

Ms Jordan Mehrtens
Company Secretary
NeuRizer Ltd
Level 11, 19 Grenfell Street
Adelaide SA 5000

By email: jordan.mehrtens@neurizer.com.au

Dear Ms Mehrtens

NeuRizer Ltd ('NeuRizer'): Price - Query

ASX refers to the following:

- A. The change in the price of NeuRizer's securities from a low of \$0.066 on 23 March 2023 to a high of \$0.11 today.
- B. The significant increase in the volume of NeuRizer's securities traded from 23 March 2023 to 28 March 2023.

Request for information

In light of this, ASX asks NeuRizer to respond separately to each of the following questions and requests for information:

- 1. Is NeuRizer aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?

In responding to this question, please consider in particular whether NeuRizer is aware of any information that its earnings for the 12 month period ending on 30 June 2023:

- (a) are likely to differ materially (downwards or upwards) from any earnings guidance it has given for the period; or
 - (b) if NeuRizer has not given any earnings guidance for the period, are otherwise likely to come as a surprise to the market (by reference to analyst forecasts for the period or, if NeuRizer is not covered by analysts, its earnings for the prior corresponding period)?
- 2. If the answer to question 1 is "yes".
 - (a) Is NeuRizer relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in NeuRizer's securities would suggest to ASX that such information may have ceased to be confidential and therefore NeuRizer may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
 - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
 - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?

-
3. If the answer to question 1 is “no”, is there any other explanation that NeuRizer may have for the recent trading in its securities?
 4. Please confirm that NeuRizer is complying with the Listing Rules and, in particular, Listing Rule 3.1.
 5. Please confirm that NeuRizer’s responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of NeuRizer with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **2:00 PM AEDT Tuesday, 28 March 2023**. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, NeuRizer’s obligation is to disclose the information ‘immediately’. This may require the information to be disclosed before the deadline set out in this paragraph and may require NeuRizer to request a trading halt immediately.

Your response should be sent to me by e-mail at **ListingsComplianceSydney@asx.com.au**. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is “yes” and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in NeuRizer’s securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

Suspension

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in NeuRizer’s securities under Listing Rule 17.3.

Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to NeuRizer’s obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that NeuRizer’s obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Release of correspondence between ASX and entity

We reserve the right to release a copy of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

Questions

If you have any questions in relation to the above, please do not hesitate to contact me.

Yours sincerely

Justin Nelson
Principal Adviser, Listings Compliance